SciSparc Ltd. SPRC announced that Clearmind Medicine Inc. CMNDF CMND CWY, has filed a provisional patent application related to metabolic syndromes including obesity, regarding the company's collaboration with Clearmind.
The patent application is the third of the collaboration, each referring to the proprietary combination of SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide (for treating obesity and its related metabolic disorders) and Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions and based on research at the Hebrew University.
"Our collaboration with Clearmind focuses on treating different addictions and binge behaviors, using the benefits of our technology and Clearmind's. Obesity, overweightness and binge eating are among the biggest health concerns of the past decade and are related to addictive behavior, and yet treating options available in the market are very limited," stated Oz Adler, SciSparc's CEO. "We believe that combining MEAI with SciSparc's CannAmide may create a great opportunity in treating these conditions."
About SciSparc
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.
Photo: Benzinga; Sources: courtesy of jarmoluk and lindsayfox via Pixabay
Related News
Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.